P
Philip L. Lorenzi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 128
Citations - 22127
Philip L. Lorenzi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 37, co-authored 96 publications receiving 17665 citations. Previous affiliations of Philip L. Lorenzi include University of Michigan & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
ElemCor: Accurate data analysis and enrichment calculation for high-resolution LC-MS stable isotope labeling experiments
Di Du,Lin Tan,Yumeng Wang,Bo Peng,John N. Weinstein,Fredric E. Wondisford,Xiaoyang Su,Philip L. Lorenzi +7 more
TL;DR: A software tool based on mass difference theory (MDT) and information from unlabeled samples (ULS) to account for resolution effects and to correct LC-MS data from isotopic labeling experiments for natural abundance and isotopic impurity is presented.
Journal ArticleDOI
MicroRNA expression profiles for the NCI-60 cancer cell panel
Paul E. Blower,Joseph S. Verducci,Shili Lin,Jin Zhou,Ji Hyun Chung,Zunyan Dai,Chang Gong Liu,William C. Reinhold,Philip L. Lorenzi,Eric P. Kaldjian,Carlo M. Croce,John N. Weinstein,Wolfgang Sadee +12 more
TL;DR: Measureting expression levels of microRNAs in the NCI-60 and incorporating the resulting data into the CellMiner program package for integrative analysis found that there does not seem to be a significant correlation between microRNA expression patterns and those of known target transcripts.
Journal ArticleDOI
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
Xinxin Peng,Zhongyuan Chen,Farshad Farshidfar,Xiaoyan Xu,Philip L. Lorenzi,Yumeng Wang,Feixiong Cheng,Lin Tan,Kamalika Mojumdar,Di Du,Zhongqi Ge,Jun Li,George Thomas,Kıvanç Birsoy,Lingxiang Liu,H. Zhang,Zhongming Zhao,Calena R Marchand,John N. Weinstein,Oliver F. Bathe,Han Liang +20 more
TL;DR: A system-level view of metabolic heterogeneity within and across cancer types is provided and knockdown of SNAI1 or RUNX1—master regulators of carbohydrate metabolic subtypes—modulates metabolic activity and drug sensitivity is demonstrated.
Journal ArticleDOI
mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities
Hongfang Liu,Petula D'Andrade,Stephanie Fulmer-Smentek,Philip L. Lorenzi,Philip L. Lorenzi,Kurt W. Kohn,John N. Weinstein,Yves Pommier,William C. Reinhold +8 more
TL;DR: New profiling studies of mRNA and microRNA expression for the 60 cell lines of the National Cancer Institute (NCI) Developmental Therapeutics program (DTP) drug screen using the 41,000-probe Agilent Whole Human Genome Oligo Microarray and the 15, thousands-feature AgILent Human microRNA Microarray V2 are presented.
Journal ArticleDOI
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
Liang Zhang,Yixin Yao,Shaojun Zhang,Yang Liu,Hui Guo,Makhdum Ahmed,Taylor Bell,Hui Zhang,Guangchun Han,Elizabeth Lorence,Maria Badillo,Shouhao Zhou,Yuting Sun,M. Emilia Di Francesco,Ningping Feng,Randy S. Haun,Renny S. Lan,Samuel G. Mackintosh,Xizeng Mao,Xingzhi Song,Jianhua Zhang,Lan V. Pham,Philip L. Lorenzi,Joseph R. Marszalek,Timothy P. Heffernan,Giulio Draetta,Philip Jones,Andrew Futreal,Krystle Nomie,Linghua Wang,Michael Wang +30 more
TL;DR: Genomic analyses of clinical specimens show that metabolic reprogramming toward oxidative phosphorylation (OXPHOS) and glutaminolysis is associated with therapeutic resistance to the Bruton’s tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma, suggesting that targeting metabolic pathways to subvert therapeutic resistance is a clinically viable approach to treat highly refractory malignancies.